A further advancement is the EnAd-variant NG-641, expressing a fibroblast activation protein (FAP)-CD3 bispecific T-cell engager (BiTE), the chemokines chemokine ligand 9 (CXCL9) and CXCL10, and interferon alpha (IFNα), in an approach to attract and stimulate T cells to attack both tumor cells and cancer-associated fibroblasts (CAFs). Here, CXCL10 is linked to neoplasm.